Ozempic May Do Something Beyond Weight Loss That Researchers Never Expected

A clinical trial published in Nature Communications on July 14, 2026 has produced the first randomized, placebo-controlled human evidence that semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, may slow biological aging at the molecular level, adding a dimension to the drug's potential benefits that researchers and pharmaceutical companies are now taking seriously. The study was led by Michael Corley at the University of California San Diego's School of Medicine and the Stein Institute for Research on Aging, and examined data from 108 adults with HIV-associated lipohypertrophy, a condition that causes excess abdominal fat to accumulate and is associated with accelerated biological aging even when the virus is well controlled with antiretroviral therapy. Half received weekly semaglutide injections and half received a placebo. Aging was measured using epigenetic clocks, scientific tools that estimate biological age by analyzing DNA methylation patterns, the chemical tags that influence how genes switch on or off throughout the body over time. Across multiple clocks tied to inflammation and the health of the blood, brain, heart, kidneys, liver, and metabolism, participants who received semaglutide showed measurably slower biological aging than those who received placebo, including a 9 percent slower pace of aging on the DunedinPACE clock and a significant slowing of processes linked to age-related disease and all-cause mortality risk on the PCGrimAge clock.

The researchers believe semaglutide may influence aging through several interconnected biological pathways. The drug reduces visceral fat, the dangerous fat stored around internal organs, as well as ectopic fat that accumulates in places where it does not belong. Lower levels of both types appear to reduce the inflammatory signals that drive cellular aging throughout the body, and GLP-1 drugs are also known to reduce chronic immune activation, one of the primary drivers of accelerated aging in people with HIV specifically. Corley said emerging data also suggest these drugs may reprogram certain cells in different organs, which could help explain why effects appear across multiple aging clocks simultaneously rather than in just one system. The study was not designed to determine whether semaglutide would produce the same results in people who do not have HIV, and the authors were careful to say that larger and more diverse trials are needed before any conclusions can be drawn about the general population. The biological case for exploring it is, however, strengthening with each new study, and this one marks a meaningful step from animal research and epidemiological observation into actual human clinical evidence.

Source:https://www.sciencedaily.com/releases/2026/07/260713084907.htm